Back to Search
Start Over
Merck's phase 3 KEYLYNK-006 trial of Keytruda plus Lynparza for certain patients with metastatic nonsquamous NSCLC fails to meet its dual primary endpoints
- Source :
- PharmaBiz. March 23, 2024
- Publication Year :
- 2024
-
Abstract
- Merck, known as MSD outside of the United States and Canada, announced that the phase 3 KEYLYNK-006 trial evaluating Keytruda, Merck's anti-PD-1 therapy, in combination with maintenance Lynparza, a PARP [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PharmaBiz
- Publication Type :
- Periodical
- Accession number :
- edsgcl.787381168